Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroendocrine Tumors 2Neuroblastoma 1Meningioma 1

Interventions

Temozolomide 6Granulocyte-Macrophage Colony-Stimulating Factor 6Cyclophosphamide 6Topotecan 5Isotretinoin 5Irinotecan 53-Iodobenzylguanidine 4naxitamab 3dinutuximab 3Vincristine 3venetoclax 2trametinib 2ribociclib 2racotumomab 2omburtamab I-131 2fludarabine 2dabrafenib 23-fluorobenzylguanidine 2sonidegib 1robatumumab 1regorafenib 1plerixafor 1palbociclib 1niraparib 1molibresib 1lorlatinib 1entrectinib 1dostarlimab 1copanlisib 1ceritinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neuroblastoma × 64Cu-SARTATE × Clear all
NCT04023331 2025-09-16

67Cu-SARTATEâ„¢ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma

Clarity Pharmaceuticals Ltd

Phase 1/2 Terminated
21 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡